SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Bio-Chem Pharma (BCHXF)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Adrian Wu who wrote (1)7/28/1996 8:24:00 PM
From: jbershad   of 43
 
Adrian

These are the results of the conference mentioned above.

3TC montherapy shows lower viral load than base line after one year,
despite a stable level of HIV antibodies compared with other drugs.

3TC/AZT combination therapy is superior to DDC/AZT therapy.

Combination therapies increase the time to drug resistance.
(e.g. AZT and 3TC prolongs both AZT and 3TC resistance.

Early interventation appears to give great benefit (More durable and
improved response.) For 3TC/AZT.

(cont)
%patients with virial loads declining Below assay detection.

regimen #patients 12 weeks #patients 24 weeks

IdV+AZT+3TC 25 88% 7 86%

IDV alone 22 41% 9 44%

AZT+3TC 24 8% 8 0%
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News